Timing of pacemaker and ICD implantation in LMNA mutation carriers
| Autor: | Ollila, Laura Helena, Nikus, Kjell, Parikka, Hannu, Weckström, Sini, Tiina, Heliö |
|---|---|
| Přispěvatelé: | Tampere University, TAYS Heart Centre, Clinical Medicine, HUS Heart and Lung Center, Clinicum, Department of Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
cardiomyopathies
Adult Male Pacemaker Artificial implantable Time Factors cardiac DNA Mutational Analysis artificial 3121 Internal medicine Heart Conduction System defibrillators Diseases of the circulatory (Cardiovascular) system Humans Registries Heart Failure and Cardiomyopathies Retrospective Studies Lamin Type B Arrhythmias Cardiac DNA Middle Aged pacemaker Defibrillators Implantable 3121 General medicine internal medicine and other clinical medicine RC666-701 Mutation Female arrhythmias Follow-Up Studies |
| Zdroj: | Open Heart Open Heart, Vol 8, Iss 1 (2021) |
| Popis: | Aims LMNA-cardiomyopathy is often associated with pathology in the cardiac conduction system necessitating device implantations. The aim was to study the timing and types of device implantations and need for re-implantations in LMNA mutation carriers. Methods We studied the hospital records of 60 LMNA mutation carriers concerning device implantations and re-implantations and their indications. Data were collected until April 2019. Results The median follow-up time from the first ECG recording to the last clinical follow-up, transplantation, or death was 7.7 (IQR=9.1) years. Altogether 61.7% (n=37) of the LMNA mutation carriers received a pacemaker or an implantable cardioverter defibrillator (ICD), and of them 27.0% (n=10) needed a device upgrade. Notably, in some patients the upgrade took place very soon after the first implantation. The first device was implanted at an average age of 47.9 years (SD=9.5), whereas the upgrade took place at an average age of 50.3 years (SD=8.1). Most upgrades were ICD implantations. Male patients underwent device upgrade more often and at a younger age than women. By the end of follow-up, 35.0% (n=21) of the patients fulfilled echocardiographic criteria for dilated cardiomyopathy, and 90.5% of them (n=19) needed pacemaker implantation. Conclusion Most LMNA mutation carriers underwent pacemaker implantation in this study. Due to the progressive nature of LMNA-cardiomyopathy, device upgrades are quite common. An ICD should be considered when the initial device implantation is planned in an LMNA mutation carrier. publishedVersion |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|